Skip to main content
main-content

The independent medical news service

Head and neck cancer

19-08-2019 | Oncology | News | Article

Early data show promise for the FGFR inhibitor rogaratinib

The FGFR inhibitor rogaratinib is well tolerated and clinically active in patients with various tumor types selected for treatment on the basis of FGFR mRNA overexpression, phase I study data show.

01-03-2019 | Oncology | News | Article

Sex disparity identified for hyperprogressive disease after immunotherapy

Women may be at greater risk than men for experiencing hyperprogression as a response to cancer treatment with immune checkpoint inhibitors, say researchers.

05-10-2018 | Oncology | News | Article

HPV-16 vaccine may boost nivolumab efficacy in HPV-16–positive cancer

The efficacy of programmed cell death protein 1 inhibition with nivolumab may be amplified by vaccination against human papillomavirus-16 in patients with incurable HPV-16–positive cancer, phase II study data suggest.

02-06-2018 | Head and neck cancer | News | Article

Disparity by sex may exist for head and neck cancer treatment, outcomes in USA

Women with head and neck cancer may be undertreated relative to their male counterparts, suggests research presented at the ASCO Annual Meeting 2018.

15-05-2018 | Head and neck cancer | News | Article

HPV positivity may improve survival in some nonoropharyngeal head and neck cancers

Human papillomavirus positivity is associated with improved survival in patients with head and neck cancer at four of six subsites in the upper aerodigestive tract, US study findings indicate.

04-05-2018 | Oncology | News | Article

In other news

This month we bring you a round-up of four trials investigating nivolumab in diverse tumors, including non-small-cell lung cancer, Hodgkin lymphoma, and nasopharyngeal carcinoma. Read on to find out more.

06-04-2018 | Oncology | News | Article

In other news

In this month’s roundup, we cover topics including laboratory eligibility criteria as a potential barrier to clinical participation and the impact of cognitive dysfunction on survival in patients with hematologic cancers. Read on to find out more.

27-03-2018 | Head and neck cancer | News | Article

No benefit of adding chemotherapy to postop radiation in cutaneous SCCHN

Phase III trial findings suggest that the addition of concomitant chemotherapy to postoperative radiotherapy does not improve the outcomes of patients with high-risk cutaneous squamous cell carcinoma of the head and neck.

15-03-2018 | Head and neck cancer | News | Article

High odds of opioid prescriptions for head and neck cancer

The likelihood of being prescribed opioids is greater for patients with head and neck cancer than for those with lung or colon cancer, findings indicate.

15-02-2018 | Head and neck cancer | News | Article

Educational gap exposed on HPV link to head and neck cancer

A survey of New York state medical students suggests many are unaware of the link between human papillomavirus infection and the risk for head and neck cancer.

14-02-2018 | Oncology | News | Article

Early alpelisib data promising in patients with PIK3CA-altered solid tumors

Researchers report “encouraging” tolerability and efficacy results from a phase Ia trial of the oral phosphatidylinositol 3-kinase α–selective inhibitor alpelisib among patients with PIK3CA-altered advanced solid tumors.

10-01-2018 | Head and neck cancer | News | Article

GERD may increase risk for upper aerodigestive tract malignancies

A US case–control study has revealed an association between gastroesophageal reflux disease and an increased risk for neoplasms of the upper aerodigestive tract in older individuals.

11-09-2017 | Head and neck cancer | News | Article

Regorafenib improves outcomes in relapsed glioblastoma patients

The phase II REGOMA trial shows that patients with recurrent glioblastoma derive a significant overall survival and disease control benefit from treatment with regorafenib over lomustine.

05-09-2017 | Oncology | News | Article

KEYNOTE-028 results point to pembrolizumab efficacy in SCLC, nasopharyngeal cancer

Findings from the multicohort, phase Ib KEYNOTE-028 trial indicate that pembrolizumab elicits durable responses and is well tolerated in patients with extensive-stage small-cell lung cancer and those with recurrent or metastatic nasopharyngeal carcinoma.

24-08-2017 | Head and neck cancer | News | Article

EBV DNA positivity may signify asymptomatic nasopharyngeal carcinoma

Patients with plasma samples repeatedly positive for Epstein–Barr virus DNA should undergo further screening for nasopharyngeal carcinoma, researchers report.

11-08-2017 | Head and neck cancer | News | Article

Mutation-directed CAR T cell therapy feasible in recurrent glioblastoma

Treatment with autologous chimeric antigen receptor T cells directed against the epidermal growth factor receptor variant III mutation is feasible and well tolerated in patients with recurrent glioblastoma, indicates a first-in-human study.

06-06-2017 | Head and neck cancer | News | Article

HPV vaccination ‘tremendous potential’ for prevention of oral HPV infection

Routine vaccination against human papillomavirus has “tremendous potential” for reducing the risk of oral HPV infection and associated malignancy, suggests research presented at the 2017 American Society of Clinical Oncology annual meeting, held in Chicago, Illinois, USA.

23-05-2017 | Head and neck cancer | News | Article

Recommendation against routine thyroid cancer screening retained

In a statement published in JAMA, the US Preventive Services Task Force upholds its 1996 recommendation against screening for thyroid cancer among asymptomatic adults.

11-05-2017 | Head and neck cancer | News | Article

Oral cavity cancer surgery in focus

Three chart reviews shed light on various aspects of surgery for oral cavity cancer, including the definition of an optimal surgical margin, postsurgical opioid use, and survival after salvage surgery.

11-01-2017 | Head and neck cancer | News | Article

HPV-negative OPSCC survival comparable with upfront surgery and CRT

A US research team has found no significant difference in overall survival between patients with human papillomavirus-negative early-stage oropharyngeal squamous cell carcinoma who received upfront surgery and those given concurrent chemoradiation.

Image Credits